Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.36 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.36 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.36 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.32 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.31 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3868098 | 0.92 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL18171337 | 0.91 | SLC28A1 (0.36) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL861369 | 0.91 | SLC28A1 (0.36) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL2732699 | 0.87 | SLC28A1 (0.37) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL23673342 | 0.86 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL3885391 | 0.84 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL6919227 | 0.82 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL4326832 | 0.82 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL1079788 | 0.82 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL17745010 | 0.81 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630650-B2 | Engineered IgA antibodies and methods of use | TIGATX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12285484-B2 | Cancer associated antibody compositions and methods of use | Absci Corporation (US) | 2025-04-29 | — | — | US | disclosed |
| US-12258420-B2 | Engineered IGA antibodies and methods of use | TIGATX, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20220204643-A1 | CANCER ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USE | Absci Corporation | 2022-06-30 | — | — | US | disclosed |
| EP-3962953-A2 | CANCER ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USE | Target Discovery Merger Sub II, LLC (US) | 2022-03-09 | — | — | EP | disclosed |
| EP-3947441-A1 | ENGINEERED IGA ANTIBODIES AND METHODS OF USE | UMC Utrecht Holding B.V. (NL) | 2022-02-09 | — | — | EP | disclosed |
| US-20220031841-A1 | CANCER ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USE | Absci Corporation | 2022-02-03 | — | — | US | disclosed |
| US-20210395395-A1 | ENGINEERED IGA ANTIBODIES AND METHODS OF USE | TIGA TX, INC. | 2021-12-23 | — | — | US | disclosed |
| US-20210380720-A1 | ENGINEERED IGA ANTIBODIES AND METHODS OF USE | TIGA TX, INC. | 2021-12-09 | — | — | US | disclosed |
| US-11091562-B2 | Engineered IGA antibodies and methods of use | UMC UTRECHT HOLDING B.V. (NL) | 2021-08-17 | — | — | US | disclosed |
| EP-3853377-A1 | CANCER ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USE | Totient, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| US-11059909-B2 | Engineered IgA antibodies and methods of use | UMC UTRECHT HOLDING B.V. (NL) | 2021-07-13 | — | — | US | disclosed |
| US-20210130462-A1 | ENGINEERED IGA ANTIBODIES AND METHODS OF USE | TIGA TX, INC. | 2021-05-06 | — | — | US | disclosed |
| US-20210122834-A1 | ENGINEERED IGA ANTIBODIES AND METHODS OF USE | TIGA TX, INC. | 2021-04-29 | — | — | US | disclosed |
| WO-2020223392-A2 | CANCER ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USE | TOTIENT, INC. (US) | 2020-11-05 | — | — | WO | disclosed |
| WO-2020197400-A1 | ENGINEERED IGA ANTIBODIES AND METHODS OF USE | UMC UTRECHT HOLDING B.V. (NL) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020061337-A1 | CANCER ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USE | TOTIENT, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| EP-0505566-A1 | BIOSPECIFIC ANTIBODY TO CANCER CELL AND ENZYME WITH PRODRUG-ACTIVATING CHARACTERISTICS | Takeda Chemical Industries, Ltd. (JP) | 1992-09-30 | — | — | EP | disclosed |
| WO-1991009134-A1 | BIOSPECIFIC ANTIBODY TO CANCER CELL AND ENZYME WITH PRODRUG-ACTIVATING CHARACTERISTICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630650-B2 | Engineered IgA antibodies and methods of use | IGLV6-57, IGSF11, FCGR2A | SLC28A1 728/4885SLC28A2 479/4885SLC29A1 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.